AnaptysBio (NASDAQ:ANAB) Stock Price Down 6.2% – Here’s What Happened

AnaptysBio, Inc. (NASDAQ:ANAB)’s share price was down 6.2% on Tuesday . The stock traded as low as $50.94 and last traded at $51.5080. Approximately 265,960 shares were traded during trading, a decline of 62% from the average daily volume of 693,087 shares. The stock had previously closed at $54.92.

AnaptysBio News Summary

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $95 price target, while raising its Q3 2026 EPS forecast to $0.00 from a projected loss of $0.03 and improving its FY2026 estimate to a loss of $1.30 per share from a loss of $2.60. The firm still expects AnaptysBio to become profitable beginning in FY2027.
• Positive Sentiment: AnaptysBio’s latest quarterly results substantially exceeded expectations, with $5.11 in EPS versus the consensus estimate of a $0.46 loss and revenue of $27.49 million versus expectations of $14.06 million. However, the profit was helped by a substantial $181.5 million tax benefit, which may limit the recurring significance of the earnings beat. AnaptysBio Swings To Profit in Q2 Reflecting $181.5 Million Tax Benefit
• Positive Sentiment: Leerink Partners continues to rate the stock Outperform and its revised $81 price target implies significant upside from the referenced $50.77 level, although the target was reduced from $90. AnaptysBio analyst information
• Neutral Sentiment: Analyst coverage remains broadly constructive: AnaptysBio has received an average “Moderate Buy” recommendation, with analysts focusing on the company’s potential transition to sustained profitability.
• Negative Sentiment: HC Wainwright cut its longer-term EPS forecasts for FY2027 through FY2030: FY2027 to $2.42 from $2.86, FY2028 to $4.57 from $5.42, FY2029 to $5.23 from $6.20, and FY2030 to $6.50 from $7.64. These reductions suggest a more cautious view of AnaptysBio’s eventual earnings power despite the unchanged Buy rating and $95 target.

Analysts Set New Price Targets

ANAB has been the topic of several recent analyst reports. Leerink Partners dropped their target price on shares of AnaptysBio from $90.00 to $81.00 and set an “outperform” rating on the stock in a research report on Wednesday. Wolfe Research restated an “outperform” rating and issued a $78.00 price objective on shares of AnaptysBio in a research note on Monday, August 31st. HC Wainwright reaffirmed a “buy” rating and set a $95.00 target price on shares of AnaptysBio in a research report on Tuesday. Cantor Fitzgerald reissued an “overweight” rating on shares of AnaptysBio in a report on Tuesday. Finally, Zacks Research lowered shares of AnaptysBio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. Twelve equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $79.15.

AnaptysBio Stock Down 5.8%

The firm has a market capitalization of $1.50 billion, a PE ratio of 9.45 and a beta of 0.71. The stock has a 50-day simple moving average of $55.57 and a 200-day simple moving average of $59.17.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Monday, September 21st. The biotechnology company reported $5.11 earnings per share for the quarter, topping the consensus estimate of ($0.46) by $5.57. AnaptysBio had a return on equity of 112.00% and a net margin of 82.37%.The company had revenue of $27.49 million during the quarter, compared to the consensus estimate of $14.06 million. During the same quarter in the prior year, the company earned ($1.30) EPS. Equities analysts forecast that AnaptysBio, Inc. will post -2.06 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in AnaptysBio during the second quarter valued at about $124,473,000. Affinity Asset Advisors LLC increased its stake in shares of AnaptysBio by 111.4% in the first quarter. Affinity Asset Advisors LLC now owns 940,000 shares of the biotechnology company’s stock worth $52,132,000 after buying an additional 495,308 shares during the period. 683 Capital Management LLC boosted its position in AnaptysBio by 18.5% during the 4th quarter. 683 Capital Management LLC now owns 648,093 shares of the biotechnology company’s stock valued at $31,420,000 after buying an additional 101,093 shares during the period. Palo Alto Investors LP purchased a new stake in shares of AnaptysBio during the second quarter worth about $40,735,508. Finally, First Light Asset Management LLC grew its stake in shares of AnaptysBio by 2.9% in the second quarter. First Light Asset Management LLC now owns 582,004 shares of the biotechnology company’s stock worth $39,285,000 after purchasing an additional 16,573 shares during the last quarter.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines for cancer and immune-mediated diseases. The company’s programs are designed to modulate immune-cell signaling and address conditions in which the immune system is either insufficiently active, as in cancer, or overly active, as in autoimmune and inflammatory disorders.

AnaptysBio’s pipeline has included rosnilimab, an investigational antibody targeting CD200R1, and other immune-cell modulators aimed at autoimmune and inflammatory diseases.